J&J Medical Connect
RYBREVANT FASPRO™

(amivantamab and hyaluronidase-lpuj)

This information is intended for US patients and caregivers to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended to promote the use of our products, nor to provide medical advice.

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj)

Patient Medical Information

Can RYBREVANT FASPRO Cause Eye Problems?

Last Updated: 12/18/2025

summary

Here is a passage from the RYBREVANT FASPRO PATIENT INFORMATION which may be helpful to address your question:

Can RYBREVANT FASPRO cause eye problems?

  • RYBREVANT FASPRO may cause serious side effects, including eye problems. RYBREVANT FASPRO can cause eye problems. Tell your healthcare provider right away if you get symptoms of eye problems which may include1:
    • eye pain
    • changes in vision
    • inflammation of eyelids
    • dry eyes
    • eye redness
    • blurred vision
    • itchy eyes
    • excessive tearing
    • sensitivity to light

Your healthcare provider may send you to see an eye specialist (ophthalmologist) if you get new or worsening eye problems during treatment with RYBREVANT FASPRO. You should not use contact lenses until your eye symptoms are checked by a healthcare provider.1

Your healthcare provider may temporarily stop, decrease your dose or completely stop your treatment with RYBREVANT FASPRO if you have serious side effects.1

These are not all of the possible side effects of RYBREVANT FASPRO.1

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.1

ADDITIONAL INFORMATION

This information is provided ONLY in response to your request and is not intended as medical advice, to promote the use of our product, or suggest using it in any manner other than as described in the PRESCRIBING INFORMATION. All decisions regarding your medical treatment should be made with your healthcare professional(s). Please contact your healthcare professional(s) to discuss the information in this response.

Please refer to the attached full PRESCRIBING INFORMATION and the PATIENT INFORMATION for RYBREVANT FASPRO.1

 

References

1 RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; https://www.jnjlabels.com/package-insert/product-monograph/prescribing-information/RYBREVANT+Faspro-pi.pdf